Gilead and No­vo Nordisk ex­pand NASH deal with new study; Pfiz­er out-li­cens­es AD­Cs to a biotech start­up

Pfiz­er has out-li­censed a pair of an­ti­body-drug con­ju­gates to Cam­bridge, MA-based Pyx­is On­col­o­gy.

Pyx­is is hand­ing over an un­spec­i­fied up­front pay­ment, mile­stones and a chunk …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER